Search
for
Sort by
Research 751–780 of 1000+
- JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases
- Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- JAK Inhibitors in the Treatment of Alopecia Areata: Efficacy, Safety, and Long-term Outcomes
- Clinical positioning and future prospects of JAK inhibitors in alopecia areata
- Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
- Case Report: Multimodal contact immunotherapy in alopecia areata: long-term clinical experience in the JAK inhibitor era
- Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways
- JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
- Irish dermatologists’ experience with JAK inhibitors in alopecia areata
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
- When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review
- Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- JAK Inhibitors in Down Syndrome: Alopecia Areata Resolution and Vitiligo Improvement with Baricitinib
- 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
- Treatment of alopecia areata with JAK inhibitors
- 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Jak inhibitors in the treatment of alopecia areata - a literature review
- JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
- Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
- Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials